DNA C

Next Previous
Drug Profile

DNA C

Alternative Names: DNA-C; DNA-HIV-C; DNA-HIV-PT123 vaccine; HIV clade C DNA vaccine; HIV DNA vaccine - EuroVac; HIV DNA vaccine - EuroVacc

Latest Information Update: 10 Jan 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator EuroVacc Foundation; GENEART; University of Regensburg
  • Developer Centre Hospitalier Universitaire Vaudois; EuroVacc Foundation; HIV Vaccine Trials Network; International AIDS Vaccine Initiative; IPPOX Foundation; Medical Research Council; MRC/UVRI Uganda Research Unit on AIDS; National Institute of Allergy and Infectious Diseases; Novartis
  • Class AIDS vaccines; DNA vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase I HIV infections

Most Recent Events

  • 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-infections(Combination therapy, Prevention) in Switzerland (IM, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-infections(Combination therapy, Prevention) in Uganda (IM, Injection)
  • 04 Nov 2017 No recent reports of development identified for phase-I development in HIV-infections(Combination therapy, Prevention) in USA (IM, Injection)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top